Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on November 4, 2021. The registrant is incorporated in California and its common stock trades on The Nasdaq Stock Market under the symbol OCX. The filing serves as a Regulation FD disclosure regarding a specific corporate event.
Key Financial Metrics
This filing is a current report regarding a non-financial event and does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. No financial statements are included in this document.
Material Changes
The material change reported is the clinical launch of the company's DetermaIOTM immunotherapy response prediction test. This event marks a significant operational milestone for the company's product portfolio.
Guidance, Outlook, and Risks
- Outlook: The filing contains forward-looking statements regarding the DetermaIOTM launch. Management cautions that actual results may differ materially from anticipated results.
- Risks: Specific risk factors are referenced in the company's Annual Report on Form 10-K under the heading "Risk Factors."
- Unusual Items: The press release attached as Exhibit 99.1 is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the clinical performance data and regulatory status of the DetermaIOTM test in the attached press release (Exhibit 99.1).
- Review the "Risk Factors" section of the most recent Form 10-K to understand potential impediments to the commercial success of the new test.
- Confirm the commercial rollout timeline and reimbursement strategy for DetermaIOTM in subsequent investor communications.
- Note that this filing does not contain updated financial results; refer to the latest 10-Q or 10-K for financial health metrics.